U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of ...

Pfizer's BRAFTOVI® (encorafenib) in combo with cetuximab and mFOLFOX6 approved by FDA for first-line treatment of metastatic colorectal cancer with BRAF V600E mutation, based on 61% overall response rate in Phase 3 BREAKWATER trial.


Related News

U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of ...

Pfizer's BRAFTOVI® (encorafenib) in combo with cetuximab and mFOLFOX6 approved by FDA for first-line treatment of metastatic colorectal cancer with BRAF V600E mutation, based on 61% overall response rate in Phase 3 BREAKWATER trial.

© Copyright 2024. All Rights Reserved by MedPath